08.04.22 -- Epigenetics: A Precision Approach

A CDMO with in-house plasmid manufacturing capabilities can help companies accelerate timelines and ensure material availability, ultimately saving time and money throughout their product life cycle.

Explore some of the major challenges in the cell and gene therapy world and how single-cell multi-omics analysis can overcome many of these issues.

Current advances in cell, gene, and tissue therapies require a rethinking of how—and where—cleanroom manufacturing facilities could be built enabling more options for sponsor process control.

Using a risk-based approach to generate an appropriate control strategy will help assure your product meets characterization and validation requirements, enabling timely approval and launch to market.

Discover how our transfection reagent demonstrates robust, non-toxic, and efficient gene expression delivery in hard-to-transfect primary hMSCs, mESCs, and induced pluripotent stem cells.

Learn how AAV characterization and stability screening are achieved with multi-angle light scattering coupled to separation methods and high-throughput dynamic light scattering.

With gene therapy, diseases that lacked cures or even treatments may be addressed with these new classes of therapeutics. This potential has spurred new investments in the drug development and commercialization space.

As drug developers face the ever-pressing need to get molecules to market as efficiently as possible, firms large and small are increasingly turning to CDMOs for help.

There are two key challenges to realizing the potential of genomic medicines, but potential technological solutions are on the horizon, and we examine each.

Learn about some of the current issues impacting the manufacture and supply of cell and gene therapy products, including manufacturing and shipping costs, upscaling, and pandemic-related issues.

Review four essential areas where biomanufacturing process infrastructure is lacking and the infrastructure needed to enable scalable, cost-effective, rapidly deployable, and adaptive biomanufacturing for the future.

This article discusses options for cell therapy process development and validation that minimize risks through quality control (QC), optimization, scaling, closing, automation, and assay development.

Read how the incorporation of transfer sets designed to support CGTs will aid in the implementation of controllable, consistent, and safe cGMP amenable manufacturing procedures.

Regulatory T cells (Tregs) are a subpopulation of T cells with the unique ability to suppress the activation of effector T cells and thereby prevent T cell function. This application note describes an optimized protocol for activation and expansion of flow-sorted Tregs with Gibco CTS Dynabeads Treg Xpander.

Discover how our technology played a critical role in CRL’s exceptionally fast development and scale-up of a saliva-based SARS-CoV-2 assay to meet the unprecedented testing need.

Accelerated clinical trial timelines for advanced therapeutics are on the rise. With fast-track status designations, it is increasingly critical for innovators to have efficient and scalable production processes.